Form 4 Valeant Pharmaceuticals For: Jul 29 Filed by: Chai-Onn Robert Roswell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 1% as investors watch Middle East supply disruptionsÂ
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Valeant Pharma (VRX) Reports Q2 EPS of $1.91
July 31, 2014 6:02 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
... More